TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone Infusion in Community-acquired Pneumonia
Brief Summary: The purpose of this study is to determine whether dexamethasone reduces the length of hospital stay in patient with a community-acquired pneumonia.


Options:
A: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone
B: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.
Brief Summary: Cutaneous leishmaniasis (CL) is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence the last two decades. It is estimated that in 2005, about of 20,000 new cases of CL were diagnosed in Colombia.

So far, pentavalent antimony compounds have been considered the treatment of choice with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their adverse events and disadvantages. Previous studies have shown that miltefosine could be a potential alternative of treatment for CL.

The main objective of this study is to evaluate the efficacy and safety of miltefosine or thermotherapy for the treatment for CL. In this study the efficacy of oral treatment of miltefosine 150 mg/day for 28 days or a thermotherapy device used for one session at 50 celsius degrees during 30 seconds will be compared with the standard treatment of intramuscular injections of 20 mg/Kg/day of pentavalent antimonials (GlucantimeÒ) for 20 days in CL parasitologically proven patients.

This trial will be conducted according to the International approved GCP (Good Clinical Practice) guidelines.


Options:
A: Arm Label: Miltefosine; Type: EXPERIMENTAL; Interventions: Drug: Miltefosine | Arm Label: Glucantime®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucantime® | Arm Label: Thermotherapy; Type: EXPERIMENTAL; Interventions: Device: Thermotherapy | Intervention Type: DRUG; Name: Miltefosine; Assigned to Arm(s): Miltefosine | Intervention Type: DEVICE; Name: Thermotherapy; Assigned to Arm(s): Thermotherapy | Intervention Type: DRUG; Name: Glucantime®; Assigned to Arm(s): Glucantime®
B: Intervention Type: DRUG; Name: Imiquimod; Assigned to Arm(s): N/A
C: Arm Label: Fluconazole; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole | Arm Label: Meglumine Antimoniate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine Antimoniate | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): Fluconazole | Intervention Type: DRUG; Name: Meglumine Antimoniate; Assigned to Arm(s): Meglumine Antimoniate
D: Arm Label: Intralesional antimony; Type: EXPERIMENTAL; Interventions: Drug: pentavalent antimony | Arm Label: Cryotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: cryotherapy | Arm Label: Topical cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo cream | Intervention Type: DRUG; Name: pentavalent antimony; Assigned to Arm(s): Intralesional antimony | Intervention Type: PROCEDURE; Name: cryotherapy; Assigned to Arm(s): Cryotherapy | Intervention Type: DRUG; Name: placebo cream; Assigned to Arm(s): Topical cream

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Continuous Intravenous Insulin Protocol Versus Subcutaneous Insulin in Acute Ischemic Stroke
Brief Summary: Hyperglycaemia is a frequent finding in acute ischemic stroke and associated with poor outcome. But the modalities of glucose lowering are still debated. This study will test the efficacy and safety of continuous intravenous insulin protocol versus usual subcutaneous insulin in acute ischemic stroke.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A
C: Arm Label: Intensive Insulin therapy; Type: EXPERIMENTAL; Interventions: Other: Intensive Insulin Therapy | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Insulin therapy | Intervention Type: OTHER; Name: Intensive Insulin Therapy; Assigned to Arm(s): Intensive Insulin therapy | Intervention Type: OTHER; Name: Conventional Insulin therapy; Assigned to Arm(s): Conventional Therapy
D: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries (PACCOCATH - FEM I)
Brief Summary: The PACCOCATH FEM study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in prevention of restenosis after femoropopliteal angioplasty.


Options:
A: Arm Label: Drug-Coated Balloon (DCB); Type: EXPERIMENTAL; Interventions: Device: Drug-Coated Balloon (DCB) | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA Balloon: Balloon Angioplasty | Intervention Type: DEVICE; Name: Drug-Coated Balloon (DCB); Assigned to Arm(s): Drug-Coated Balloon (DCB) | Intervention Type: DEVICE; Name: PTA Balloon: Balloon Angioplasty; Assigned to Arm(s): Standard PTA
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Device: paclitaxel coated balloon catheter (device with drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: paclitaxel coated balloon catheter (device with drug) | Intervention Type: DEVICE; Name: paclitaxel coated balloon catheter (device with drug); Assigned to Arm(s): 1, 2
C: Arm Label: Stent; Type: EXPERIMENTAL; Interventions: Device: Zilver® PTX™ Stent | Intervention Type: DEVICE; Name: Zilver® PTX™ Stent; Assigned to Arm(s): Stent
D: Arm Label: Drug Eluting Balloon; Type: EXPERIMENTAL; Interventions: Device: IN.PACT Amphirion | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard PTA | Intervention Type: DEVICE; Name: IN.PACT Amphirion; Assigned to Arm(s): Drug Eluting Balloon | Intervention Type: DEVICE; Name: Standard PTA; Assigned to Arm(s): Standard PTA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Evaluation of Open vs. Laparoscopic Operation of Ventral Incisional Eventrations. A Swedish Multicenter Study
Brief Summary: This purpose of this study is to compare the recovery after an operation of an incisional hernia within the limits of the rectus muscles of the abdominal wall. The use of a mesh in the repair of a postoperative hernia is considered obligatory. Placement of a retromuscular mesh is done by open or laparoscopic surgery. Focus is on the recovery phase assuming a less painful recovery after a laparoscopic procedure.


Options:
A: Arm Label: 1: tacks; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tack fixation of mesh | Arm Label: 2: glue; Type: EXPERIMENTAL; Interventions: Procedure: glue fixation of mesh | Intervention Type: PROCEDURE; Name: tack fixation of mesh; Assigned to Arm(s): 1: tacks | Intervention Type: PROCEDURE; Name: glue fixation of mesh; Assigned to Arm(s): 2: glue
B: Arm Label: small hernias - suture repair; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Arm Label: small hernias - mesh repair; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Arm Label: large hernias - sublay mesh; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Arm Label: large hernias - onlay mesh; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Intervention Type: PROCEDURE; Name: abdominal wall reconstruction; Assigned to Arm(s): large hernias - onlay mesh, large hernias - sublay mesh, small hernias - mesh repair, small hernias - suture repair
C: Arm Label: Group A; Type: OTHER; Interventions: Procedure: Laparoscopic incisional or ventral hernia repair | Arm Label: Group B; Type: OTHER; Interventions: Procedure: Laparoscopic incisional or ventral hernia repair | Intervention Type: PROCEDURE; Name: Laparoscopic incisional or ventral hernia repair; Assigned to Arm(s): Group A, Group B
D: Intervention Type: PROCEDURE; Name: Retromuscular Mesh repair of midline incisional hernia; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Laparoscopic repair of midline incisional hernia; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients
Brief Summary: The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.


Options:
A: N/A
B: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients
Brief Summary: The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.


Options:
A: Arm Label: SelPCT; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite, Procedure: Procalcitonin guided therapy | Arm Label: SelKon; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite | Arm Label: PlacPCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Procedure: Procalcitonin guided therapy | Arm Label: PlacKon; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sodium-selenite; Assigned to Arm(s): SelKon, SelPCT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PlacKon, PlacPCT | Intervention Type: PROCEDURE; Name: Procalcitonin guided therapy; Assigned to Arm(s): PlacPCT, SelPCT
B: Arm Label: PCT; Type: EXPERIMENTAL; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Intervention Type: BEHAVIORAL; Name: a strategy based on PCT guided AB therapy; Assigned to Arm(s): Guidelines, PCT
C: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients
Brief Summary: The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.


Options:
A: Arm Label: A; Type: NO_INTERVENTION; Interventions: Behavioral: Academic Detailing by the Antimicrobial Utilization Team (AUT) | Intervention Type: BEHAVIORAL; Name: Academic Detailing by the Antimicrobial Utilization Team (AUT); Assigned to Arm(s): A
B: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
C: Intervention Type: BEHAVIORAL; Name: Quality improvement strategies; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients
Brief Summary: The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.


Options:
A: Arm Label: SelPCT; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite, Procedure: Procalcitonin guided therapy | Arm Label: SelKon; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite | Arm Label: PlacPCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Procedure: Procalcitonin guided therapy | Arm Label: PlacKon; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sodium-selenite; Assigned to Arm(s): SelKon, SelPCT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PlacKon, PlacPCT | Intervention Type: PROCEDURE; Name: Procalcitonin guided therapy; Assigned to Arm(s): PlacPCT, SelPCT
B: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
C: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients
Brief Summary: The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.


Options:
A: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
C: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
D: Arm Label: 8 days of antibiotic treatment; Type: EXPERIMENTAL; Interventions: Drug: Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin, Drug: compare 8 to15 days of antibiotic treatment | Arm Label: 15 days antibiotic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: compare 8 to15 days of antibiotic treatment | Intervention Type: DRUG; Name: Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; Assigned to Arm(s): 8 days of antibiotic treatment | Intervention Type: DRUG; Name: compare 8 to15 days of antibiotic treatment; Assigned to Arm(s): 15 days antibiotic treatment, 8 days of antibiotic treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study
Brief Summary: Conventional hemodialysis requires transient systemic anticoagulation to prevent blot clotting after contact with the extracorporeal circuit. However, low molecular weight heparin (LMWH) or unfractioned heparin are contra-indicated in dialysis patients at risk for hemorrhagic complications. In this setting, several procedures theoretically allow dialysis without systemic heparinization, but randomized studies to compare them are lacking. The gold standard is the use of iterative rises of the extra corporeal circuit with isotonic saline (" rises "). Two emerging procedures are increasingly used : continuous pre-dilution of the arterial line (" pre-dilution ") and the use of a specific dialysis membrane (NEPHRAL 400 ST) coated with heparin immediately before use (" heparin adsorption ").


Options:
A: Arm Label: Tinzaparin; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin, Drug: Placebo (for Unfractionated Heparin) | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin, Drug: Placebo (for Tinzaparin) | Intervention Type: DRUG; Name: Tinzaparin; Assigned to Arm(s): Tinzaparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin | Intervention Type: DRUG; Name: Placebo (for Tinzaparin); Assigned to Arm(s): Unfractionated Heparin | Intervention Type: DRUG; Name: Placebo (for Unfractionated Heparin); Assigned to Arm(s): Tinzaparin
B: Arm Label: Dialysis without systemic heparinization; Type: EXPERIMENTAL; Interventions: Procedure: Dialysis without systemic heparinization | Intervention Type: PROCEDURE; Name: Dialysis without systemic heparinization; Assigned to Arm(s): Dialysis without systemic heparinization
C: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
D: Arm Label: EVODIAL dialyzer and Selectbag citrate; Type: EXPERIMENTAL; Interventions: Device: EVODIAL dialyzer and Selectbag citrate | Arm Label: Regional citrate anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Regional citrate anticoagulation | Intervention Type: DEVICE; Name: EVODIAL dialyzer and Selectbag citrate; Assigned to Arm(s): EVODIAL dialyzer and Selectbag citrate | Intervention Type: DEVICE; Name: Regional citrate anticoagulation; Assigned to Arm(s): Regional citrate anticoagulation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Open Label, Blinded-endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM in Subjects With Mild-to-moderate Essential
Brief Summary: This prospective chronotherapy trial will investigate the potential differing efficacy of ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon awakening from nighttime sleep or at bedtime, to diurnally active patients with grade 1 or 2 essential hypertension, who will be evaluated by 48-hour ABPM before and after pharmacologic intervention. The benefits from this trial may be extremely important, taking into account

1. the high prevalence of non-dipping among patients with essential hypertension
2. the need for a proper 24-hour BP control with particular emphasis on the regulation of nighttime resting BP mean
3. the lacking information on the administration-time dependent effects on BP of ramipril, a widely used ACEI in doses of 5-10 mg/day.


Options:
A: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A
B: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): 1, 2 | Intervention Type: DEVICE; Name: ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2

Answer: C